

Lorlatinib Market

Market Report | 2025-05-01 | 254 pages | Datastring Consulting

AVAILABLE LICENSES:

- Multi User License \$1399.00

Report description:

Description

The market, for Lorlatinib was estimated at \$358.3 million in 2024; and it is anticipated to increase to \$581.3 million by 2030 with projections indicating a growth to around \$870.1 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 8.4% over the forecast period.

Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

Table of Contents:

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

- 2.1: Axioms & Postulates
- 2.2: Market Introduction & Research Methodology Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

- 3.1: Market Overview Drivers / Restraints / Opportunities / M4 Factors
- 3.2: Market Trends
- 3.2.1: Introduction & Narratives
- 3.2.2: Market Trends Impact Analysis (Short, Medium & Long Term Impacts)
- 3.3: Supply Chain Analysis
- 3.4: Porter's Five Forces Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Lorlatinib Market Size, Opportunities & Strategic Insights, by Dosage Form

- 4.1: Tablets
- 4.2: Capsules

Chapter 5: Global Lorlatinib Market Size, Opportunities & Strategic Insights, by Treatment Areas

5.1: Lung Cancer

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 5.2: ALK-positive NSCLC
- 5.3: Metastatic Conditions
- 5.4: Others

Chapter 6: Global Lorlatinib Market Size, Opportunities & Strategic Insights, by End Users

- 6.1: Hospitals
- 6.2: Pharmaceutical Companies
- 6.3: Research Institutes
- 6.4: Others

Chapter 7: Global Lorlatinib Market Size, Opportunities & Strategic Insights, by Sales Channel

- 7.1: Online Pharmacies
- 7.2: Retail Pharmacies
- 7.3: Hospital Pharmacies

Chapter 8: Lorlatinib Market, by Region

- 8.1: North America Lorlatinib Market Size, Opportunities, Key Trends & Strategic Insights
- 8.1.1: U.S.
- 8.1.2: Canada
- 8.2: Europe Lorlatinib Market Size, Opportunities, Key Trends & Strategic Insights
- 8.2.1: Germany
- 8.2.2: France
- 8.2.3: UK
- 8.2.4: Italy
- 8.2.5: The Netherlands
- 8.2.6: Rest of FU
- 8.3: Asia Pacific Lorlatinib Market Size, Opportunities, Key Trends & Strategic Insights
- 8.3.1: China
- 8.3.2: Japan
- 8.3.3: South Korea
- 8.3.4: India
- 8.3.5: Australia
- 8.3.6: Thailand
- 8.3.7: Rest of APAC
- 8.4: Middle East & Africa Lorlatinib Market Size, Opportunities, Key Trends & Strategic Insights
- 8.4.1: Saudi Arabia
- 8.4.2: United Arab Emirates
- 8.4.3: South Africa
- 8.4.4: Rest of MEA
- 8.5: Latin America Lorlatinib Market Size, Opportunities, Key Trends & Strategic Insights
- 8.5.1: Brazil
- 8.5.2: Mexico
- 8.5.3: Rest of LA
- 8.6: CIS Lorlatinib Market Size, Opportunities, Key Trends & Strategic Insights
- 8.6.1: Russia
- 8.6.2: Rest of CIS

Chapter 9: Competitive Landscape

- 9.1: Competitive Dashboard & Market Share Analysis
- 9.2: Company Profiles (Overview, Financials, Developments, SWOT)
- 9.2.1: Pfizer Inc

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.2: Takeda Pharmaceutical Company Limited
- 9.2.3: Novartis AG
- 9.2.4: Bristol-Myers Squibb
- 9.2.5: Boehringer Ingelheim
- 9.2.6: AstraZeneca PLC
- 9.2.7: Eli Lilly and Company
- 9.2.8: Roche Holding AG
- 9.2.9: GlaxoSmithKline PLC
- 9.2.10: Sanofi
- 9.2.11: Bayer AG
- 9.2.12: Merck & Co. Inc.

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com



☐ - Print this form

To place an Order with Scotts International:

Lorlatinib Market

Market Report | 2025-05-01 | 254 pages | Datastring Consulting

☐ - Complete the re	elevant blank fields and sign			
Send as a scanr	ned email to support@scotts-intern	ational.com		
ORDER FORM:				
Select license	License			Price
	Multi User License			\$1399.00
			VAT	
upl			Total	
	ant license option. For any questions pl			
□ VAT WIII be added a	t 23% for Polish based companies, indi	viduais and EU based Cor	ripanies who are unable to provide a	valid EU vat Nullibe
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / N	IIP number*	
Address*		City*		
Zip Code*		Country*		
		Date	2025-06-08	
		Signature		

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com